Duke University Medical Center, Durham, North Carolina.
New York-Presbyterian/Columbia University Medical Center, New York, New York.
J Heart Lung Transplant. 2020 Aug;39(8):774-781. doi: 10.1016/j.healun.2020.03.002. Epub 2020 Mar 20.
In a randomized controlled trial (MOMENTUM 3), the HeartMate 3 (HM3) fully magnetically levitated centrifugal-flow left ventricular assist device (LVAD) demonstrated superiority over the HeartMate II (HMII) axial-flow LVAD. These findings were driven by hemocompatibility-related outcomes, but infection-related outcomes were not altered by device choice. In this trial-level analysis, we analyzed the clinical patterns of infection-related outcomes over 2 years of support.
In MOMENTUM 3, 1,020 patients were implanted with either the HM3 (n = 515) or HMII (n = 505) pump. Clinical characteristics and morbidity- and mortality-related outcomes were evaluated to identify predictors associated with major infectious complications, using univariable and multivariable models.
The cumulative number of infections at 2 years was 1,213 (634 HM3 and 579 HMII), and major infection occurred in 58% of patients with the HM3 and 56% of patients with the HMII (p = 0.57). Infections of a local nature unrelated to pump components were most common (n = 681/1,213; 56%), followed by driveline-associated infection (n = 329/1,213; 27%), sepsis (n = 194/1,213; 16%), and other events (n = 9/1,213; 0.7%). Bacterial pathogens were implicated in 806 of 1,213 events (66%); significant predictors of infection included sex (women vs men; hazard ratio [HR]: 1.38, p = 0.003), pre-implant use of intra-aortic balloon pump (HR: 1.33, p = 0.02), pre-implant history of cardiac surgery (HR: 1.28, p = 0.01), and body mass index ≥ 30 (HR: 1.40, p < 0.0001). Most deaths in those with infection occurred owing to non-infectious causes.
Infection is the most common adverse effect in patients implanted with contemporary continuous-flow LVADs, with most such events unrelated to the pump or its peripheral components. Whether chronic mechanical circulatory devices confer an immunomodulatory effect pre-disposing to infection warrants closer scrutiny to understand and ameliorate this morbidity.
在一项随机对照试验(MOMENTUM 3)中,HeartMate 3(HM3)全磁悬浮离心流左心室辅助装置(LVAD)在疗效上优于 HeartMate II(HMII)轴流 LVAD。这些发现是由血液相容性相关结果驱动的,但设备选择并没有改变与感染相关的结果。在这项试验水平的分析中,我们分析了 2 年支持期间与感染相关的结果的临床模式。
在 MOMENTUM 3 中,1020 名患者植入了 HM3(n=515)或 HMII(n=505)泵。使用单变量和多变量模型评估临床特征和发病率及死亡率相关结果,以确定与主要感染并发症相关的预测因素。
2 年时累计感染数为 1213 例(HM3 为 634 例,HMII 为 579 例),HM3 组 58%的患者和 HMII 组 56%的患者发生了严重感染(p=0.57)。最常见的是与泵组件无关的局部性质的感染(n=681/1213;56%),其次是与输液线相关的感染(n=329/1213;27%)、败血症(n=194/1213;16%)和其他事件(n=9/1213;0.7%)。1213 例感染事件中 806 例(66%)涉及细菌病原体;感染的显著预测因素包括性别(女性与男性;风险比[HR]:1.38,p=0.003)、植入前使用主动脉内球囊泵(HR:1.33,p=0.02)、植入前心脏手术史(HR:1.28,p=0.01)和 BMI≥30(HR:1.40,p<0.0001)。感染患者的大多数死亡是由非传染性原因引起的。
感染是植入当代连续流 LVAD 患者最常见的不良反应,大多数此类事件与泵或其外周组件无关。慢性机械循环装置是否具有预先诱发感染的免疫调节作用,这值得更仔细地研究,以了解和改善这种发病率。